<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A minor population of blood cells deficient of <z:chebi fb="0" ids="24410">glycosylphosphatidylinositol</z:chebi> (GPI)-anchored membrane proteins is often detected in patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA), though the clinical significance of such <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>)-type cells remains unclear </plain></SENT>
<SENT sid="1" pm="."><plain>To clarify this issue, we studied 164 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) for the presence of CD55(-)CD59(-) granulocytes and red blood cells using sensitive flow cytometry </plain></SENT>
<SENT sid="2" pm="."><plain>Among the different subgroups of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, a significant increase (ie, at least 0.003%) of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>-type cells was detected in 21 of 119 patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA); this frequency (17.6%) of RA patients with increased <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>-type cells (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>(+) patients) was much lower than what we previously reported (52.0%) for AA patients </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>(+) RA patients had distinct clinical features compared with RA patients without increased <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>-type cells (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>(-) patients), such as less pronounced morphologic abnormality of blood cells, more severe <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, lower rates of karyotypic abnormality (4.8% vs 32.8%) and of progression to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (0% vs 6.2%), higher probability of response to <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> therapy (77.8% vs 0%), and higher incidence of HLA-DR15 (90.5% vs 18.5%) </plain></SENT>
<SENT sid="4" pm="."><plain>These data indicate that the presence of a minor population of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>-type cells suggests a benign type of <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo>, probably caused by an immunologic mechanism </plain></SENT>
<SENT sid="5" pm="."><plain>To choose an appropriate therapy, peripheral blood should be tested using sensitive flow cytometry for the presence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>-type cells in <z:hpo ids='HP_0000001'>all</z:hpo> patients with <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> before treatment </plain></SENT>
</text></document>